Geron Corporation Presents New Data at ASH 2025 Highlighting the Relationship Between Treatment-Emergent Cytopenias and Clinical Benefit of RYTELO® (Imetelstat) in Lower-Risk MDS
Geron Corporation Oral presentation from pooled analyses of the IMerge population suggests that treatment-emergent cytopenias may reflect on-target…